Agriculture Victoria Services is an agricultural company that provides crops and irrigation services.

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

MJN U.S. Holdings LLC, part of Reckitt Benckiser Group Plc, is a company headquartered in the United States that functions as an investment holding company.

Novartis Vaccines & Diagnostics, Inc. manufactures and markets health care and nutritional products. The company was founded in 1986 and is headquartered in East Hanover, NJ.

Twin Health is a Precision Health platform combining Sensors, Machine Learning, and Medical Science to reverse chronic diseases and improve human metabolic health. They are backed by leading VC firms Iconiq Capital, Sequoia Capital, Perceptive Advisors, Corner Ventures, LTS Investments, Helena, and Sofina with $183M in Series A, Series B, and Series C funding. Twin has developed unique patent-pending technology (5 patents filed) to analyze complex biosignals from wearable sensors, predict metabolic outcomes using ML, and recommend highly-personalized treatments based on the metabolic profile of each patient.

University Health Network (UHN) is a healthcare and medical research organization in Toronto, Ontario, Canada. It is the largest such research organization in Canada and North America, ranking first in Canada for total research funding. It was named Canada's top research hospital by Research Infosource in 2015, 2016 and 2017. It was created in 1986 by the Government of Ontario through the merger of four major hospitals: Toronto General Hospital, Toronto Western Hospital, with the Princess Margaret Cancer Centre, and the Toronto Rehabilitation Institute merged in with The Toronto Hospital in 1999 and the name changed to the University Health Network. All four hospitals are affiliated with the Faculty of Medicine at the University of Toronto and serve as teaching hospitals for resident physicians, nurses, and other healthcare professions. UHN also operates The Michener Institute, an applied health sciences college that opened in 1958.

Biocrates is a developer of a metabolomics platform designed to support the discovery and validation of biomarkers for complex diseases. The company's metabolomics platform comprises an automated sample preparation workflow integrated with sensitive mass-spectrometric methods and software that controls sample management, data collection, and analysis to identify hundreds of metabolites, enabling physicians to acquire comprehensive metabolic information quickly and reliably.

LanzaTech New Zealand Ltd., part of LanzaTech Global, Inc., is a company headquartered in Auckland, New Zealand, that develops software for producing ethanol fuel.

CropDesign NV develops traits for cereal crops. It delivers agronomic traits for the global commercial seed markets. The firm focuses on enhancing grain yield in crops such as corn and rice, and increasing biomass of energy crops. Its platform, TraitMill, lows evaluating the effect of genes on the performance of plants under different growing conditions, including drought and low nutrient stress. The company was founded in 1998 and is headquartered in Zwijnaarde, Blgium.

Chiron Corporation (/ˈkaɪrɒn/ KY-ron) was an American multinational biotechnology firm based in Emeryville, California that was acquired by Novartis on April 20, 2006. It had offices and facilities in eighteen countries on five continents. Chiron's business and research was in three main areas: biopharmaceuticals, vaccines, and blood testing. Chiron's vaccines and blood testing units were combined to form Novartis Vaccines and Diagnostics, while Chiron BioPharmaceuticals was integrated into Novartis Pharmaceuticals. In 2014, Novartis completed the sale of its blood transfusion diagnostics unit to Grifols and announced agreements for the sale of its vaccines unit to GlaxoSmithKline.

Target Discovery, Inc. provides scientific research services. It discovers, validates, and utilizes protein isoforms to improve clinical diagnosis and the management of diseases. The firm’s products address prostate cancer aggressiveness, and chemotherapy selection in breast and ovarian cancer. The company was founded by Luke V. Schneider in 1999 and is headquartered in Palo Alto, CA.

Metabolon is a technology company, develops analytical methods and software for biomarker discovery using metabolomics. It offers a biochemical profiling platform that analyzes and identifies biochemicals in the research of pharmaceutical, biotech, agriculture, cosmetic, and consumer products. Metabolon provides a unique, real-time fingerprint of biological system to reveal novel discoveries and realize the promise of precision medicine. The company can deliver an instantaneous snapshot of the entire physiology of a living being at a discreet point in time, as well as identify changes in that system brought about the impact of the disease, medical intervention, diet, or the environment. This deep and comprehensive view of the metabolome provides biological insights that cannot be revealed through any other research methodology, enabling life sciences researchers and drug developers to discover answers to some of biology’s most difficult questions. Metabolon was founded in 2000 and headquartered in Durham, North Carolina.

Bayer HealthCare Ltd., established on 1995-08-25, Business scope includes licensed projects:pharmaceutical production;Pharmaceutical commissioned production;Drug Wholesale;Drug import and export;Production of Class II Medical Devices;Production of Class III Medical Devices;Class III medical device business;food sales;Health food production;food production;Production of formula food for special medical purpose;Cosmetic production;Production of hygiene products and single-use medical products;Disinfectant production(Free of Hazardous Chemicals).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)General project:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Medical Research and Experimental Development;Production of Class I Medical Devices;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Cosmetics Wholesale;Cosmetics Retail;internet sales(Except for products that require a license for sale);Food import and export;software development;software sales;Retailing of computer software, hardware and auxiliary equipment;Wholesale of computer software, hardware and auxiliary equipment;Manufacturing of computer software, hardware and peripheral equipment;Software outsourcing service;Information Consulting Service(Not including licensing information consulting services);Information Technology Consulting Services;Special Equipment Repair;Import and export;Technology Import and Export;Import and export agency;Sales of hygiene products and single-use medical products;Disinfectant sales(Free of Hazardous Chemicals);Manufacturing of daily chemical products;Sales of daily chemical products.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)(Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Nubiyota LLC is a privately held company in Teaneck, NJ and is a Single Location business. Categorized under Biological Products Manufacturers.Their records show it was established in 2013 and incorporated in New Jersey. Current estimates show this company has an annual revenue of 85071 and employs a staff of approximately 1.

STALICLA is a clinical stage, precision molecular neuroscience biotech company with a mature pipeline for patients with Neurodevelopmental Disorders (NDDs) and Neuropsychiatric disorders. STALICLA’s unique approach addresses a principal weakness in the drug development process for NDD’s and neuropsychiatric disorders: behavior is a terrible biomarker. Clinical psychiatric and neurodevelopmental diagnoses encompass a broad diversity of underlying biology. This has contributed to drug development failure by diluting true responders in a population of patients with heterogeneous biology. STALICLA’s technology platform, DEPI, discovers biologically based endophenotypes within classical neuropsychiatric diagnostic groups. The AI/ML engine converges molecular data with human genetic information and non-behavioral clinical signs and symptoms, to define biologically related subgroups and create testable clinical hypotheses related to that biology. The DEPI platform has already completed several successful clinical validations, through the identification and biological validation of two distinct subgroups of patients with Autism Spectrum Disorder, ASD-Phenotype1 and ASD-Phenotype2, together with their predicted tailored treatment candidates (STP1 and STP2); as well as the blindly and retrospective calling “high” responder patients to previously failed drug candidates with high specificity, sensitivity, and positive predictive value. Further the completion of STP1 Phase 1b in 2022, STP1 will enter clinical Phase 2 in 2023; as well as STP2, a Phase 2 ready asset in licensed in Q4 ’22. Additionally, STALICLA will be advancing STP7, a recently in-licensed Phase 3 ready asset from Novartis, with strong potential for a neuropsychiatric indication, and whose clinical development will be fully financed by a non-dilutive funding to be announced in Feb. STALICLA is currently preparing its next stage of growth, to advance its pipelines and to scale its platform towards revenue generation.

J.M. Huber Corporation combines imagination, inspiration and innovation to enhance the performance of thousands of consumer and industrial products across a variety of industries. Our engineered materials are part of daily life—from dental silicas that make smiles whiter and brighter, to hydrocolloids that improve everything from foods to pharmaceuticals. Our engineered wood products are breaking new ground with residential and commercial builders. Our sustainable forestry practices help ensure the responsible environmental stewardship of timberlands. Since our founding in 1883 by Joseph Maria Huber, we have transformed ideas into products that meet the challenges of an ever-evolving world. A family-owned company, Huber’s profitable growth has spanned three centuries and six generations. We remain one of the most successful privately held companies headquartered in the United States, guided by enduring principles centered on Environmental, Health & Safety Sustainability, Ethical Behavior, Respect for People and Excellence.